This stock is no longer traded. It was delisted on July 21, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
XOMA Corporation operates as a biotech royalty aggregator, acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology companies. This model provides sellers with non-dilutive, non-recourse funding to advance drug development or for general corporate purposes, while XOMA Royalty builds a diversified portfolio spanning multiple therapeutic areas and development stages. The company focuses on development-stage assets with significant commercial potential, partnered with well-capitalized entities, including royalties on marketed products and clinical programs. XOMA Corporation also engages in transactions with distressed biotechs, acquiring and monetizing their intellectual property to generate returns. With over 120 assets, it plays a key role in the biotech financing ecosystem by bridging funding gaps and supporting innovation in human health therapies across regions including the United States, Europe, and Asia Pacific. Founded in 1981 and headquartered in Emeryville, California, XOMA Corporation maintains a lean operation dedicated to royalty aggregation.
Website2200 Powell Street
EmeryVille, CA, 94608
United States
The latest articles about XOMA.
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to...
Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity. Chief Financial Officer Tavo Espinoza said Ligand has
Summary of Apr 27's posts. Generated by AI.
Summary of Sep 6's posts. Generated by AI.
Summary of Apr 27's posts. Generated by AI.
Summary of Apr 27's posts. Generated by AI.
Investors talking about XOMA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.